tbuckley/cabot-search huggingface dataset:
A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma
Authors: Shuji Ozaki, Takayuki Saitoh, Hiroshi Handa, Hirokazu Murakami, Kenshi Suzuki, Naoki Takezako, Jun Konishi, Kazutaka Sunami, Yoshiaki Kuroda, Mitsuhiro Itagaki, Hideki Asaoku, Eiichi Nagura, Kazuyuki Shimizu
Journal: Blood (2015)
Critical and Opposing Effects of T Cell-Derived TNFα and Interferon-γ on IL-17 Induction Assessed in Vitro and in Vivo Following Allogeneic Bone Marrow Transplantation
Authors: Minghui Li, Kai Sun, Mark Hubbard, Doug Redelman, Angela Panoskaltsis-Mortari, Sergei Nedospasov, Dennis Taub, Bruce Blazar, Lisbeth A. Welniak, William J. Murphy
Journal: Blood (2008)
2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels
Authors: Daniel A Pollyea, Holbrook E Kohrt, Bing Zhang, James L. Zehnder, David P. Schenkein, Valeria Fantin, Kimberly Straley, Aparna Vasanthakumar, Omar Abdel-Wahab, Ross L Levine, Lucy Godley, Bruno C. Medeiros
Journal: Blood (2011)
PTU-034 Stricture Formation after Endoscopic Mucosal Resection of Large Colonic Polyps
Authors: R Kassam, J Subhani
Journal: Gut (2016)

<h3>Introduction</h3> Post endoscopic resection strictures are seen in oesophagus in up to 20–30% of circumferential resection.<sup>1,2</sup> Probably due to the greater circumference of the colon these have not been described in Colorectal EMR. However with larger lesions being tackled the prospect of this complication arises. <h3>Methods</h3> Details of lesions assessed for EMR by a single endoscopist (JMS) were kept prospectively. Non-pedunculated polyps &gt;59 mm were assessed to see if the patients developed significant strictures. Only those who developed obstructive symptoms were considered significant. <h3>Results</h3> here were 801 non Ip lesions, with 749 attempted resections on the database. There were 80 lesions &gt;59 mm and 72 proceeded to attempted resection (8 not attempted all subsequently diagnosed as cancer). The 72 lesions will be the focus of the study. Mean size 68 mm (60–120 mm), 36 rectal, 15 other left-sided, 9 caecal, 12 other right-sided lesions. 23 (32%) involved 25–50% of the circumference, 35 (49%) 50–75% and 14 (19%) involved 75–100%. In 47/72 cases the resection was completed at the first session. In 25 cases the initial resection was stopped due to suspicion of CA, technical difficulty or length of procedure. 11/25 patients subsequently underwent surgery, 14 further endoscopic resection. After completed endoscopic resections 1 other patient required surgery. 60/72 treated endoscopically. 4 subsequently developed symptoms from strictures requiring dilation all had 75–100% circumferential involvement. 2 sigmoid (70, 100 mm), 2 rectal (90, 100 mm). All had LGD histology and only received a small amount of APC. 3 were completed in a single session, one required 2 sessions. Only 11 patients had &gt;75% circumferential involvement and had complete endoscopic resection. 4 developed strictures. The 4 were treated with endoscopic dilation successfully. However, one patient who had twice been dilated to 15 mm, on a third session was dilated to 18 mm causing a perforation and subsequently required surgery. <h3>Conclusion</h3> In large colorectal EMR if &lt;75% of circumference involved there is little chance of functional significant structure. However if &gt;75% there maybe a 40% chance of a functional significant stricture. Appropriate measures such as laxative and a 4 week endoscopic assessment is appropriate. <h3>References</h3> 1 Bahin FF, <i>et al. Endoscopy</i> 2016 Jan;<b>48</b>(1):71–4. 2 Komeda Y, <i>et al. Endosc Int Open</i> 2014 Jun;<b>2</b>(2) E58–E64. <h3>Disclosure of Interest</h3> None Declared
Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,
Authors: Tilmann Bochtler, Ute Hegenbart, Axel Benner, Dirk Hose, Anja Seckinger, Kai Neben, Sascha Dietrich, Claus R Bartram, Anthony D. Ho, Hartmut Goldschmidt, Anna Jauch, Stefan O Schonland
Journal: Blood (2011)
A cases of pertuzumab + trastuzumab + docetaxel was effective for inflammatory breast cancer with HER2-positive
Authors: Yuji Yamashita, Yuko Tanaka, Meiko Nishimura, Toru Mukohara, Seishi Kono, Shintaro Takao, Hironobu Minami
Journal: Annals of Oncology (2015)
High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib
Authors: Paolo Vigneri, Fabio Stagno, Stefania Stella, Alessandra Cupri, Stefano Forte, Michele Massimino, Agostino Antolino, Clementina Caracciolo, Laura Nocilli, Stefana Impera, Caterina Musolino, Diamante Turri, Mario Russo, Carmela Anna Maria Tomaselli, Michele Rizzo, Maurizio Musso, Fortunato Morabito, Luciano Levato, Livia Manzella, Martin C Mueller, Andreas Hochhaus, Francesco Di Raimondo
Journal: Blood (2015)
Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis
Authors: Charlotte Buchanan, Azharuddin Mohammed, Eleanor Cox, Katrin Köhler, Bernard Canaud, Maarten W. Taal, Nicholas M. Selby, Susan Francis, Chris W. McIntyre
Journal: Journal of the American Society of Nephrology (2016)

Hemodynamic stress during hemodialysis (HD) results in recurrent segmental ischemic injury (myocardial stunning) that drives cumulative cardiac damage. We performed a fully comprehensive study of the cardiovascular effect of dialysis sessions using intradialytic cardiac magnetic resonance imaging (MRI) to examine the comparative acute effects of standard HD versus hemodiafiltration (HDF) in stable patients. We randomly allocated 12 patients on HD (ages 32–72 years old) to either HD or HDF. Patients were stabilized on a modality for 2 weeks before undergoing serial cardiac MRI assessment during dialysis. Patients then crossed over to the other modality and were rescanned after 2 weeks. Cardiac MRI measurements included cardiac index, stroke volume index, global and regional contractile function (myocardial strain), coronary artery flow, and myocardial perfusion. Patients had mean±SEM ultrafiltration rates of 3.8±2.9 ml/kg per hour during HD and 4.4±2.5 ml/kg per hour during HDF ( P =0.29), and both modalities provided a similar degree of cooling. All measures of systolic contractile function fell during HD and HDF, with partial recovery after dialysis. All patients experienced some degree of segmental left ventricular dysfunction, with severity proportional to ultrafiltration rate and BP reduction. Myocardial perfusion decreased significantly during HD and HDF. Treatment modality did not influence any of the cardiovascular responses to dialysis. In conclusion, in this randomized, crossover study, there was no significant difference in the cardiovascular response to HDF or HD with cooled dialysate as assessed with intradialytic MRI.
Intensification of Chemotherapeutic Regimens and Hematopoietic Stem Cell Transplantation Are Responsible for Improved Overall Survival in Adult Acute Lymphoblastic Leukemia in a Single Center Over the Last Forty Years
Authors: Estrella Carrillo, Nancy Rodriguez, Juan Francisco Dominguez, Jose Gonzalez, Jose Francisco Falantes, Isabel Montero, M. Luz Martino, Francisco Márquez-Malaver, Ricardo Parody, Estefania Garcia-Guerrero, Jose Antonio Perez-Simón, Ildefonso Espigado
Journal: Blood (2011)
Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)
Authors: Meritxell Nomdedeu, Xavier Calvo, Dolors Costa, Montserrat Arnan, Helena Pomares, Guillermo Sanz, David Valcarcel, Elisa Luño, Fernando Ramos, Maria Diaz-Campelo, Rosa Collado, Raquel de Paz, Jose-Francisco Falantes, Carme Pedro, Jordi Esteve, Rafael Andreu, Maria-Teresa Ardanaz, Joaquin Sanchez-Garcia, Mar Tormo, Maria-Teresa Cedena, Beatriz Arrizabalaga, Bernardo Gonzalez, Victor Marco, Salut Brunet, Arturo Pereira
Journal: Blood (2015)
Host Pharmacogenetic Factors Significantly Contribute to Refinement of Prognosis in Children with Acute Lymphoblastic Leukemia (ALL): Result From the Malaysia-Singapore (Ma-Spore) ALL 2003 Study
Authors: Yi Lu, Shirley Kow Yin Kham, Arrifin Hany, Ah Moy Tan, Thuan Chong Quah, Allen Eng Juh Yeoh
Journal: Blood (2011)
TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT
Authors: Joseph Antonios, Horacio Soto, Joey Orpilla, Namjo Shin, Richard Everson, Linda Liau, Robert Prins
Journal: Neuro-Oncology (2015)
Improved Survival of Patients with HIV-Related Systemic B-Cell Non-Hodgkin’s Lymphoma (NHL) Expressing the Epstein-Barr Virus (EBV) in Malignant Cells Provided Patients Received HAART with Lymphoma Therapy.
Authors: Hatoon Ezzat, Douglas Filipinko, Linda M. Vickars, Paul F. Galbraith, Charles H. Li, Kevin Murphy, Julio S.G. Montaner, Marianne Harris, Robert S. Hogg, Suzanne Vercauteren, Chantal S. Leger, Leslie Zypchen, Heather A. Leitch
Journal: Blood (2006)
Is overlap of respiratory and limb muscle weakness at weaning from mechanical ventilation associated with poorer outcomes?
Authors: Clément Medrinal, Guillaume Prieur, Éric Frenoy, Yann Combret, Francis Edouard Gravier, Tristan Bonnevie, Antoine Poncet, Aurora Robledo Quesada, Bouchra Lamia, Olivier Contal
Journal: Intensive Care Medicine (2016)
SAT0364 Pentraxin 3 as Biomarker in Assessment of Disease Activity in Takayasu Arteritis
Authors: P.K. Devarasetti, S.K. Appani, R.V.P. Irlapati, L. Rajasekhar
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In Takayasu arteritis (TA) Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are used to monitor disease activity. Thirty percent of patients with active inflammation have normal ESR while 40% without vascular inflammation have elevated ESR.<sup>1</sup> Pentraxin 3 (PTX3) produced in vascular wall during inflammation, may be a better biomarker of disease activity. <h3>Objectives</h3> To compare PTX3 levels in TA patients with healthy controls and to compare the accuracy of PTX3 levels with high sensitive CRP (hs CRP) and ESR in distinguishing active from inactive disease. <h3>Methods</h3> Cross sectional prospective study conducted from 2014 to 2015.Forty consecutive TA patients fulfilling 1990 American College of Rheumatology criteria for TA and 20 healthy controls were included. Disease activity was assessed by Physician Global Assessment (PGA), Indian Takayasu Arteritis Score (ITAS)<sup>2</sup> and ITAS-ESR. Serum PTX3 levels (pg/ml) was measured in TA patients and controls, hsCRP (ng/ml)and ESR (mm/hr)were measured in TA patients. Based on PGA patients were divided into active, grumbling and inactive disease.Serum PTX3, hs CRP and ESR were expressed as mean (SD). ROC were constructed for serum PTX3, hs CRP and ESR in differentiating active from inactive disease. p value &lt;0.05 was considered significant. SPSS Software (version 21) was used. <h3>Results</h3> Mean age of TA patients and Healthy controls was 27 (7.9), 20 (3.4) years respectively.90% patients were female.Mean disease duration was 3.4 (3.1) years (range 1–12 yrs). Weight loss, fatigue, anorexia were the presenting symptoms followed by claudication. There were 14 patients with active disease, 8 with grumbling disease and 18 with inactive disease.Mean (SD) ITAS in patients with active disease 5.9 (3.5) was significantly higher than in patients with grumbling disease 0.9 (1.2) or inactive disease 0.6 (1). Mean ITAS-ESR in active disease was higher than in grumbling and inactive disease but not different between grumbling and inactive disease. <h3>Conclusions</h3> PTX3 performed better than hs CRP and ESR in differentiating active from inactive disease. Grumbling disease could not be differentiated from inactive disease using ITAS/ITAS-ESR. Inflammatory markers did not perform well in differentiating grumbling disease from active or inactive disease in TA. <h3>References</h3> Lupi-Herrera E et al Takayasu9s arteritis. Clinical study of 107 cases. Am Heart J. 1977; 93:94–103 Misra R et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013;52:1795–801 <h3>Disclosure of Interest</h3> None declared
Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease
Authors: Arnold Bolomsky, Dirk Hose, Martin Schreder, Anja Seckinger, Tobias Meißner, Bernard Klein, Daniel Heintel, Sabine Pfeifer, Heinz Ludwig, Niklas Zojer
Journal: Blood (2012)
AB0442 Spectrum and Drug Resistance of Bacteria Isolated from Hospitalized Patients with Systemic Lupus Erythematosus
Authors: D. Chen, Z. Zhan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In recent decades, the leading cause of death in patients with <i>systemic lupus</i> erythematosus (SLE) has changed from active disease to infection. The spectrum of infectious agents in SLE patients varies significantly among different ethnic groups. Furthermore, multiple drug resistance (MDR) pathogens have become the biggest concern worldwide, and the situation is even more serious in China. <h3>Objectives</h3> To investigate the spectrum and antibiotic resistant pattern of bacterial infection in patients hospitalized with SLE. <h3>Methods</h3> We collected the clinical and microbiological data from hospitalized SLE patients with bacterial infection between June 2005 and June 2015 and then conducted retrospective analyses. <h3>Results</h3> Among our sample of 3815 hospitalized patients, 258 episodes had microbiological defined bacterial infection. In terms of isolated microorganisms, gram-negative bacteria (GNB) were predominant over gram-positive bacteria (GPB) (178 isolates vs. 90 isolates). In the GNB, Escherichia coli (24.6%) was the most common isolate, followed by Acinetobacter baumannii (13.4%) and Klebsiella pneumoniae (9.0%). For GPB, coagulase negative Staphylococcus (CNS, 13.4%) was most commonly documented followed by Staphylococcus aureus (11.2%) and other GPB. Overall, MDR bacteria were detected in 26.9% of the isolates. Extended-spectrum beta-lactamase (ESBL) producers were expressed mainly in Escherichia coli (30/66, 45.5%) and Klebsiella pneumoniae (7/24, 29.2%). The proportion of multi-drug resistant acinetobacter baumannii (MDR-AB) in the sample was 36.1%. Eight of Staphylococcus aureus (8/30, 26.7%) were found to be methicillin-resistant Staphylococcus aureus (MRSA), and fourteen of CNS (14/36, 38.9%) were considered methicillin-resistant CNS (MRSCNS). <h3>Conclusions</h3> Predominance of GNB with emerging of MDR isolates was the notable features of bacterial infection in Chinese SLE patients. Therefore rational use of antibiotic will be urgently needed to reduce the morbidity and mortality of patients with SLE. <h3>Disclosure of Interest</h3> None declared
Pharmacokinetic Modeling of Fludarabine to Control Exposure and Improve Outcomes after Reduced Intensity Conditioning Transplantation
Authors: Kinjal Sanghavi, Anthony C. Wiseman, Qing Cao, Erica D. Warlick, Claudio G Brunstein, Richard Brundage, John Rogosheske, Andy Kurtzweil, John E. Wagner, Daniel J. Weisdorf, Pamala A. Jacobson
Journal: Blood (2014)
Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Authors: Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, Stefano Luminari, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella
Journal: Blood (2015)
Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations
Authors: Tina Bagratuni, Efstathios Kastritis, Maria Roussou, Dimitrios Christoulas, Efthimios Kostouros, Marianna Politou, Evangelos Terpos, Meletios Athanasios Dimopoulos
Journal: Blood (2011)
Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
Authors: Katarina Le Blanc, Francesco Frassoni, Lynne Ball, Edoardo Lanino, Berit Sundberg, Helena Lonnies, Helene Roelofs, Giorgio Dini, Andrea Bacigalupo, Franco Locatelli, Willem F. Fibbe, Olle Ringden
Journal: Blood (2006)
Pharmacodynamics, Pharmacokinetics, and Tolerability of a B-Cell Specific Antibody-Targeted Chemotherapeutic Agent, Anti-CD79b-MCC-DM1, in Cynomolgus Monkeys
Authors: Marna Williams, Dongwei Li, Reina Fuji, Franklin Fuh, Saileta Prabhu, Bing Zheng, Kristi Elkins, Shang-Fan Yu, Josefa Chuh, Christine Tan, Joanne Hongo, Helga Raab, Judy Young, Sarajane Ross, Katherine Kozak, Dan Eaton, Susan D. Spencer, Kirsten A Poon, Paul Fielder, Jay Tibbitts, Karen Berry, William Manning, Vanitha Ramakrishnan, Allen Ebens, Andrew G. Polson
Journal: Blood (2008)
Dermatology’s Balanced Diet
Authors: Bobbak Mansouri, Chad D. Housewright
Journal: JAMA Dermatology (2016)

We were interested to read the Notable Note by Higgins et al,1 and we agree that dermatology is indeed “the sweetest specialty.” However, practicing moderation with sweets would be wise. Fortunately, classical dermatologic descriptions span the spectrum of tastes and foods.
PWE-047 Metronidazole is A Less Effective Therapy for Small Intestinal Bacterial Overgrowth
Authors: A El Habishi, J McLaughlin, W Johns, E Leitao, P Paine
Journal: Gut (2016)

<h3>Introduction</h3> Choice of antibiotic treatment in patients who test positively for Small Intestinal Bacterial Overgrowth (SIBO) can be difficult. No controlled trial has examined the clinical efficacy of antibiotics in SIBO. This study aimed to identify which antibiotics are the most effective in treating SIBO in a real world retrospective cohort. <h3>Methods</h3> 520 adult patients (360 female, 160 male, mean age 49) who underwent hydrogen and glycocholate-methane breath tests for a suspicion of SIBO between the dates 01/01/2010 and 31/12/2013 were evaluated. The clinical information of patients who tested positively in both tests was recorded. Information was also gathered as to the antibiotic they were prescribed and whether they received symptomatic benefit from their treatment. <h3>Results</h3> A total of 90 patients who tested positive were prescribed antibiotics (59 female, 31 male, mean age 56). 69 (76.7%) of these patients benefitted from their management. 32 patients who tested positive were given cyclical antibiotics. The efficacy of cyclical antibiotics compared with the combined efficacy rates of other antibiotic regimes in treating patients with a positive breath test result was 93.8%. (93.8% vs 67.2%, Chi-square = 8.1, p = 0.004). 15 patients who tested positive were given rifaximin. The efficacy of rifaximin in treating patients with a positive breath test result compared with the combined efficacy of other antibiotic regimes was 80%. (80% vs 76% Chi-square = 0.112, p = 0.738). 18 patients who tested positive were given metronidazole. The efficacy of metronidazole in treating patients who tested positive in the breath tests compared with combined efficacy rates of other antibiotics was much lower at 50% (50% vs 83%, Chi-square = 8.9441, p = 0.0028). <h3>Conclusion</h3> Metronidazole appeared inferior to rifaximin monotherapy for treating SIBO. Cyclical antibiotics appeared most effective. These findings should be explored further in randomised controlled prospective trials to determine the optimal treatment regime. <h3>Disclosure of Interest</h3> None Declared
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Authors: Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel-Vinay, Nathalie Chaput, Alexander Eggermont, Aurélien Marabelle, Jean-Charles Soria, Charles Ferté
Journal: Clinical Cancer Research (2016)

Purpose: While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive disease or HPD) under these agents have been described, suggesting potentially deleterious effects of these drugs. The prevalence, the natural history, and the predictive factors of HPD in patients with cancer treated by anti-PD-1/PD-L1 remain unknown.Experimental Design: Medical records from all patients (N = 218) prospectively treated in Gustave Roussy by anti-PD-1/PD-L1 within phase I clinical trials were analyzed. The tumor growth rate (TGR) prior ("REFERENCE"; REF) and upon ("EXPERIMENTAL"; EXP) anti-PD-1/PD-L1 therapy was compared to identify patients with accelerated tumor growth. Associations between TGR, clinicopathologic characteristics, and overall survival (OS) were computed.Results: HPD was defined as a RECIST progression at the first evaluation and as a ≥2-fold increase of the TGR between the REF and the EXP periods. Of 131 evaluable patients, 12 patients (9%) were considered as having HPD. HPD was not associated with higher tumor burden at baseline, nor with any specific tumor type. At progression, patients with HPD had a lower rate of new lesions than patients with disease progression without HPD (P < 0.05). HPD is associated with a higher age (P < 0.05) and a worse outcome (overall survival). Interestingly, REF TGR (before treatment) was inversely correlated with response to anti-PD-1/PD-L1 (P < 0.05) therapy.Conclusions: A novel aggressive pattern of hyperprogression exists in a fraction of patients treated with anti-PD-1/PD-L1. This observation raises some concerns about treating elderly patients (>65 years old) with anti-PD-1/PD-L1 monotherapy and suggests further study of this phenomenon. Clin Cancer Res; 23(8); 1920-8. ©2016 AACRSee related commentary by Sharon, p. 1879.